PharmSource - Contract Small Molecule API Manufacturing Industry by the Numbers - 2019 Edition

5.1 Definition of the Small Molecule API CMO Universe
5.2 Industry Demographics

6.1 Controlled Substance Small Molecule API Manufacturing Facilities
6.2 Small Molecule API Manufacturing Facilities with Containment

7.1 Geographical Distribution of Controlled Substance Facilities
7.2 Geographical Distribution of Facilities with Containment Capabilities
7.3 European Analysis

12.1 Appendix Tables
12.2 Bibliography
12.3 Primary Research - Key Opinion Leaders in this Report
12.4 About the Authors
12.5 Contact Us
12.6 Disclaimer

Table 1: Revenue Composition and Specialized Capabilities of Leading CMOs, 2018
Table 2: Percentage of Companies by Revenue Tier with Specialized Capabilities (Dedicated Contract and Public CMOs Only)
Table 3: CMO Small Molecule API Manufacturing Facility Acquisitions, 2015-2018
Table 4: CMO Small Molecule API Manufacturing Facilities Acquired by Company M&A and Divestment, 2015-2018
Table 5: CMO Small Molecule API Manufacturing Facilities Acquired by PE, 2015-2018
Table 6: Geographic Reach of CMOs with Small Molecule API Manufacturing, 2018
Table 7: Public CMOs’ API Manufacturing Facilities and Controlled Substance/Containment Capabilities, 2018

Figure 1: Geographic Reach of the Small Molecule API CMO Universe, 2018 (Public CMOs Only)
Figure 2: Public CMOs with Small Molecule Manufacturing Capability by Annual Contract Revenue, 2018
Figure 3: Geographic Distribution by Headquarters of Public Small Molecule API Dedicated Contract CMOs
Figure 4: Top CMOs by Small Molecule API Manufacturing Facilities
Figure 5: Top CMOs by Small Molecule API Facilities with Containment Capabilities
Figure 6: Top CMOs by Small Molecule API Facilities with Controlled Substance Capabilities
Figure 7: Oncology Pipeline by Developmental Stage and Molecule Type
Figure 8: Geographical Distribution of All CMO Small Molecule API Manufacturing Facilities
Figure 9: Geographical Distribution of Controlled Substance Small Molecule Manufacturing Facilities
Figure 10: Geographical Distribution of Small Molecule Manufacturing Facilities with Containment Capabilities
Figure 11: NMEs Requiring Special Handling, 2008-2018
Figure 12: Geographical Distribution of Small Molecule Contract Manufacturing Facilities in Europe, 2018
Figure 13: Distribution of European Small Molecule Contract Manufacturing Facilities with Containment Capabilities, 2018
Figure 14: Distribution of Controlled Substance European Small Molecule Contract Manufacturing Facilities, 2018
Figure 15: Public CMOs with Small Molecule Manufacturing Capability by Accumulated Contract Revenue, 2018
Figure 16: CMO Small Molecule API Manufacturing Facility with Containment Acquisitions, 2015-2018
Figure 17: Controlled Substance CMO Small Molecule API Manufacturing Facility Acquisitions, 2015-2018
Figure 18: All M&A Deals Involving Small Molecule API Containment Facilities, by Most Active CMOs, 2015-2018
Figure 19: All M&A Deals Involving Small Molecule API Controlled Substance Facilities, by Most Active CMOs, 2015-2018 29